A guide to immunotherapy for COVID-19

Frank L. van de Veerdonk; Evangelos Giamarellos-Bourboulis; Peter Pickkers; Lennie Derde; Helen Leavis; Reinout van Crevel; Job J. Engel; W. Joost Wiersinga; Alexander P.J. Vlaar; Manu Shankar-Hari; Tom van der Poll; Marc Bonten; Derek C. Angus; Jos W.M. van der Meer; Mihai G. Netea

doi:10.1038/s41591-021-01643-9

A guide to immunotherapy for COVID-19

Frank L. van de Veerdonk^*, Evangelos Giamarellos-Bourboulis, Peter Pickkers, Lennie Derde, Helen Leavis, Reinout van Crevel, Job J. Engel, W. Joost Wiersinga, Alexander P.J. Vlaar, Manu Shankar-Hari, Tom van der Poll, Marc Bonten, Derek C. Angus, Jos W.M. van der Meer, Mihai G. Netea

^*Corresponding author for this work

Peter Gorer Department of Immunobiology

Research output: Contribution to journal › Article › peer-review

158 Citations (Scopus)

Abstract

Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

Original language	English
Pages (from-to)	39-50
Number of pages	12
Journal	Nature Medicine
Volume	28
Issue number	1
Early online date	21 Jan 2022
DOIs	https://doi.org/10.1038/s41591-021-01643-9
Publication status	Published - Jan 2022

Access to Document

10.1038/s41591-021-01643-9

Cite this

van de Veerdonk, F. L., Giamarellos-Bourboulis, E., Pickkers, P., Derde, L., Leavis, H., van Crevel, R., Engel, J. J., Wiersinga, W. J., Vlaar, A. P. J., Shankar-Hari, M., van der Poll, T., Bonten, M., Angus, D. C., van der Meer, J. W. M., & Netea, M. G. (2022). A guide to immunotherapy for COVID-19. Nature Medicine, 28(1), 39-50. https://doi.org/10.1038/s41591-021-01643-9

@article{72710b6e6fb4456a85fc2b6a6d773d5c,

title = "A guide to immunotherapy for COVID-19",

abstract = "Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.",

author = "{van de Veerdonk}, {Frank L.} and Evangelos Giamarellos-Bourboulis and Peter Pickkers and Lennie Derde and Helen Leavis and {van Crevel}, Reinout and Engel, {Job J.} and Wiersinga, {W. Joost} and Vlaar, {Alexander P.J.} and Manu Shankar-Hari and {van der Poll}, Tom and Marc Bonten and Angus, {Derek C.} and {van der Meer}, {Jos W.M.} and Netea, {Mihai G.}",

note = "Funding Information: F.L.v.d.V. gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (Vidi grant from ZonMW & ZonMW project nr 10430012010010).M.G.N. was supported by a Spinoza grant of the Netherlands Association for Scientific Research. Publisher Copyright: {\textcopyright} 2022, Springer Nature America, Inc.",

year = "2022",

month = jan,

doi = "10.1038/s41591-021-01643-9",

language = "English",

volume = "28",

pages = "39--50",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A guide to immunotherapy for COVID-19

AU - van de Veerdonk, Frank L.

AU - Giamarellos-Bourboulis, Evangelos

AU - Pickkers, Peter

AU - Derde, Lennie

AU - Leavis, Helen

AU - van Crevel, Reinout

AU - Engel, Job J.

AU - Wiersinga, W. Joost

AU - Vlaar, Alexander P.J.

AU - Shankar-Hari, Manu

AU - van der Poll, Tom

AU - Bonten, Marc

AU - Angus, Derek C.

AU - van der Meer, Jos W.M.

AU - Netea, Mihai G.

N1 - Funding Information: F.L.v.d.V. gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (Vidi grant from ZonMW & ZonMW project nr 10430012010010).M.G.N. was supported by a Spinoza grant of the Netherlands Association for Scientific Research. Publisher Copyright: © 2022, Springer Nature America, Inc.

PY - 2022/1

Y1 - 2022/1

N2 - Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

AB - Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

UR - http://www.scopus.com/inward/record.url?scp=85123401345&partnerID=8YFLogxK

U2 - 10.1038/s41591-021-01643-9

DO - 10.1038/s41591-021-01643-9

M3 - Article

AN - SCOPUS:85123401345

SN - 1078-8956

VL - 28

SP - 39

EP - 50

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

A guide to immunotherapy for COVID-19

Abstract

Access to Document

Other files and links

Fingerprint

Cite this